149.85
price up icon0.60%   +0.90
after-market  アフターアワーズ:  149.85 
loading

Johnson & Johnson (JNJ) 最新ニュース

TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

pulisher
Zacks Investment Research

3 Top Dividend Stocks to Maximize Your Retirement Income

pulisher
Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

pulisher
Zacks Investment Research

What Is the Dividend Payout for Johnson & Johnson Stock?

pulisher
The Motley Fool

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

pulisher
Zacks Investment Research

Got $1,000? 3 Dividend Stocks to Buy and Hold Forever

pulisher
The Motley Fool

The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips

pulisher
Zacks Investment Research

Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy

pulisher
Benzinga

Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix

pulisher
Zacks Investment Research

A Look at Pharma ETFs Post Q1 Earnings

pulisher
Zacks Investment Research

5 Relatively Secure And Cheap Dividend Stocks To Invest In - May 2024

pulisher
Seeking Alpha

Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims

pulisher
Zacks Investment Research

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

pulisher
Zacks Investment Research

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

pulisher
Zacks Investment Research

3 Dividend Growth Stocks that Just Raised Their Payouts

pulisher
The Motley Fool

5 Expected Dividend Increases In May 2024

pulisher
Seeking Alpha

Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market

pulisher
Benzinga

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

pulisher
Zacks Investment Research

3 No-Brainer Stocks to Buy With $200 Right Now

pulisher
The Motley Fool

Johnson & Johnson Is a King of Dividend Safety

pulisher
The Motley Fool

2 Top Growth Stocks to Buy Right Now and Hold Forever

pulisher
The Motley Fool

Better Dividend Stock: AbbVie or Johnson & Johnson?

pulisher
The Motley Fool

Johnson & Johnson Stock: Buy, Sell, or Hold?

pulisher
The Motley Fool

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

pulisher
Zacks Investment Research

Are You Looking for a High-Growth Dividend Stock?

pulisher
Zacks Investment Research

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

pulisher
Zacks Investment Research

5 Stocks in Focus on Their Recent Dividend Hike

pulisher
Zacks Investment Research

Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?

pulisher
Zacks Investment Research

The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson

pulisher
Zacks Investment Research

These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years

pulisher
The Motley Fool

Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

pulisher
The Motley Fool

4 Stocks to Watch on Their Recent Dividend Hikes

pulisher
Zacks Investment Research

Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably

pulisher
Seeking Alpha

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

pulisher
Zacks Investment Research

10 High-Yield Dividend Aristocrats Perfect For An Uncertain Market

pulisher
Seeking Alpha

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

pulisher
Zacks Investment Research

The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron

pulisher
Zacks Investment Research

Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson

pulisher
Zacks Investment Research

Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future

pulisher
Benzinga

Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results

pulisher
Benzinga

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

pulisher
Zacks Investment Research

Company News for Apr 17, 2024

pulisher
Zacks Investment Research

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

pulisher
Benzinga

Why Johnson & Johnson Stock Got Tossed by the Market Today

pulisher
The Motley Fool

Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript

pulisher
The Motley Fool

Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What's Driving Markets Tuesday?

pulisher
Benzinga

Building Permits Come in Lower Than Expected

pulisher
Zacks Investment Research

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

pulisher
Zacks Investment Research

Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH

pulisher
Zacks Investment Research

Johnson & Johnson (JNJ) Reports Q1 Earnings: What Key Metrics Have to Say

pulisher
Zacks Investment Research
drug_manufacturers_general MRK
$130.23
price up icon 0.52%
$160.40
price down icon 0.03%
drug_manufacturers_general NVS
$100.21
price up icon 0.61%
$312.86
price up icon 1.81%
drug_manufacturers_general PFE
$28.18
price down icon 0.32%
大文字化:     |  ボリューム (24 時間):